Dive in

Developers have become increasingly powerful decision makers and influencers within organizations, with purchasing powers of their own and dedicated budgets—particularly in light of the explosive growth of GenAI.

Drug design is both a natural fit and a unique challenge for generative AI, given large but messy datasets, time and cost of real-world testing, and the complexity of human trials.

While navigating this exciting yet complex landscape may seem daunting for startups, lessons from past tech waves, along with a thoughtful, strategic approach, can help illuminate the path forward.

Developing an elevator pitch is a powerful exercise for helping entrepreneurs sharpen their thinking around a potential new business idea. Coming up with innovative ideas is a challenge in itself, and founders are often caught spinning their wheels, struggling to bring clarity and focus to their vision.

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

OpenAI’s ChatGPT reached 100 million monthly active users just two months after launch, setting the new standard for the fastest-growing consumer application in history. The landmark achievement underscored the strength of generative AI’s pull in consumer markets—surpassing even the breakthroughs of the internet and smartphones.

With Adobe’s proposed $20 billion acquisition, Figma’s tale of disruption is a Cinderella story. Unique insights informed the company’s product decisions, allowing it to become the target of a record-setting acquisition.

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.

At Manifest 2023, Menlo’s Steve Sloane moderated a panel with top supply chain experts to discuss current trends and shifts within the industry, as well as their predictions for the future.

At Menlo Ventures, we’ve invested in fintech for a long time and, despite the volatility of the last two years, believe there’s still a lot to be excited about.

Economic downturns force us to get back to basics: The cost of new capital and low valuation multiples—even for top-performing public companies—force startups to make substantial progress per dollar to get a term sheet, much less an up round.

Cancer remains one of the leading causes of death in the U.S. and worldwide.

Supply chain is having a moment.

Software developers spend their days chasing the elusive “flow state:” headphones on, Slack notifications paused, dev environment humming along, context switching to a minimum, and delivering a significant amount of valuable code and/or solving a hard problem.

History may not repeat itself, but it often rhymes.